TROPHOGEN INC
Rockville, MD · Biotech · Private
Recombinant equine chorionic gonadotropin (reCG) agonist for animal reproduction
trophogen.com →- Grants
- $9.3M
- 13 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 19
- 6 granted · 13 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420152016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Novel High Affinity VEGF Analogs For Targeted Imaging of Thyroid Cancer | $765,782 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Novel and Affordable Neoglycosylated, Long Acting Superactive Analog of Human FSH for Infertility | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel Recombinant High-Affinity, Long- and Dual-Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and Cattle | $138,880 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Novel and Affordable Neoglycosylated, Long Acting Superactive Analog of Human FSH for Infertility | $825,420 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer. | $285,070 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Recombinant High-Affinity, Long- and Dual-Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and Cattle | $733,166 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Recombinant High-Affinity, Long- and Dual-Acting Equine CG Analogs for Improved and More EthicalReproduction in Pigs and Cattle | $1,460,767 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Novel and Affordable Neoglycosylated, Long Acting Superactive Analog of Human FSH for Infertility | $942,701 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer. | $1,557,540 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer. | $778,770 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Recombinant High-Affinity, Long- and Dual-Acting Equine CG Analogs for Improved and More Ethical Reproduction in Pigs and Cattle | $727,601 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer. | $433,685 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Long Acting rhTSH Superagonist Analogs for Improved Diagnostic Imaging, Thyroglobulin Stimulation and Therapy of Thyroid Cancer. | $345,085 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1559 | TRANSPORIN, INC. | — | — |
| 1560 | Karuna Therapeutics | — | — |
| 1561 | Sudo Biosciences | — | $63M |
| 1562 | TROPHOGEN INC | — | — |
| 1563 | Anjon Biologics Inc. | — | — |
| 1564 | STEM PHARM, INCORPORATED | — | — |
| 1565 | RELMADA THERAPEUTICS, INC. | — | $33M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Glycoprotein Hormone Long-Acting Superagonistsapplication
- Glycoprotein Hormone Long-Acting Superagonistsapplication
- Glycoprotein Hormone Long-Acting Superagonistsgranted
- Glycoprotein Hormone Long-Acting Superagonistsgranted
- Glycoprotein Hormone Long-acting Superagonistsgranted
- Follicle Stimulating Hormone Superagonistsapplication
- Glycoprotein Hormone Long-Acting Superagonistsgranted
- Glycoprotein Homone Long-acting Superagonistsgranted
- VEGF Analogs and Methods of Useapplication
- Vegf Analogsgranted
- Follicle Stimulating Hormone Superagonistsapplication
- Follicle Stimulating Hormone Superagonistsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.